Ziemssen Focke, Stahl Andreas, Dimopoulos Spyridon
Department für Augenheilkunde, Eberhard-Karls-Universität Tübingen.
Augenheilkunde, Universitäts-Augenklinik Freiburg.
Klin Monbl Augenheilkd. 2017 Dec;234(12):1483-1492. doi: 10.1055/s-0043-115393. Epub 2017 Aug 23.
Health care research has emerged as an approach to assess and improve quality of care and patient outcomes in the real world. It also has the potential to reduce healthcare costs by providing evidence to guide healthcare decisions.Randomised controlled trials (RCTs) theoretically offer the ideal study design to support treatment decisions. In RCTs, randomisation (formal chance) determines treatment allocation, which prevents selection bias from distorting the parameters of anti-VEGF treatment effects. Despite this advantage, only a minority of patients qualify for inclusion in neovascular age-related macular degeneration or diabetic macular oedema trials, which limits the validity of the results to the whole patient population seen in clinical practice. The evidence base for anti-VEGF is deficient in terms of matching the characteristics of patients encountered in clinical practice, and a more representative sample of older people and those with significant disability must be included in future trials. RCTs often do not address other knowledge gaps, including treatment delay, comparisons for less frequent types of CNV, monitoring of rare or late toxicity events or systemic safety.Observational studies, or studies in which treatment allocation occurs independently of investigators' choice or randomisation, can complement RCTs by providing data that is more relevant to the circumstances under which intravitreal therapy is routinely practiced. However, it is important to be aware of the strengths and limitations of such observational study designs, in order to optimise the design as well as the analytic techniques. Selection bias and loss-to-follow-up cause make comprehensive interpretation and careful analysis necessary. Future reports should focus on time-to-event analysis, as this is much less prone to loss-to-follow-up and improves adherence of (functionally) one-eyed or good responders. Observational studies and pragmatic trials can test new hypotheses and possible license extensions. The bearing of RCT findings on day-to-day practice can then be assessed. The data can be interpreted in a more meaningful manner by practicing clinicians if evidence is integrated from a variety of different study designs and methodologies.
卫生保健研究已成为一种在现实世界中评估和改善医疗质量及患者治疗结果的方法。它还有通过提供证据来指导医疗决策从而降低医疗成本的潜力。随机对照试验(RCTs)理论上提供了支持治疗决策的理想研究设计。在随机对照试验中,随机化(正式的机会)决定治疗分配,这可防止选择偏倚扭曲抗血管内皮生长因子(anti-VEGF)治疗效果的参数。尽管有这一优势,但只有少数患者符合纳入新生血管性年龄相关性黄斑变性或糖尿病性黄斑水肿试验的条件,这限制了研究结果对临床实践中所见全体患者人群的有效性。抗血管内皮生长因子的证据基础在匹配临床实践中遇到的患者特征方面存在不足,未来试验必须纳入更具代表性的老年人样本和有严重残疾的患者。随机对照试验往往未解决其他知识空白,包括治疗延迟、较少见类型的脉络膜新生血管(CNV)的比较、罕见或晚期毒性事件的监测或全身安全性。观察性研究,即治疗分配独立于研究者选择或随机化的研究,可通过提供与玻璃体内治疗常规实施情况更相关的数据来补充随机对照试验。然而,了解此类观察性研究设计的优势和局限性很重要,以便优化设计及分析技术。选择偏倚和失访使得进行全面解释和仔细分析成为必要。未来的报告应侧重于事件发生时间分析,因为这更不易出现失访情况,并能提高(功能上)单眼或反应良好者的依从性。观察性研究和实用性试验可检验新假设及可能的许可扩展。然后可评估随机对照试验结果对日常实践的影响。如果将来自各种不同研究设计和方法的证据整合起来,临床医生就能以更有意义的方式解释数据。